CytoAgents
A clinical stage biotechnology company focused on the development of innovative pharmaceutical products for the treatment of life-threatening symptoms associated with Cytokine Release Syndrome.
Launch date
Employees
Market cap
-
Enterprise valuation
€25—38m (Dealroom.co estimates May 2023.)
Pittsburgh Pennsylvania (HQ)
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
N/A | Angel | ||
| N/A | $100k | Seed | |
| N/A | N/A | Convertible | |
$1.6m | Grant | ||
$250k | Grant | ||
$50.0k | Seed | ||
$2.0m | Grant | ||
| N/A | $6.1m | Early VC | |
* | $7.0m | Series A | |
| Total Funding | €15.5m | ||
Recent News about CytoAgents
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.